Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...
Zacks Small Cap Research on MSN1d
RANI: Impressive Bioavailability for RT-116
RANI READ THE FULL RANI RESEARCH REPORT On February 5 th , Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of ...
Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$11m last week
To get a sense of who is truly in control of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), it is important to understand the ownership structure of the business. And the group that holds the biggest ...
Rani Therapeutics announces data from semaglutide via RaniPill capsule trial
Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...
Janney Montgomery Scott LLC Purchases New Shares in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)
Janney Montgomery Scott LLC purchased a new stake in shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Free Report) during the fourth quarter, according to the company in its most recent ...
Rani Therapeutics reports positive obesity treatment study
SAN JOSE, Calif. - Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company with a market capitalization of $48.3 million, today announced promising results from a ...
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of “Buy” from Analysts
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) has been given an average recommendation of “Buy” by the six ratings firms that are currently covering the stock, Ratings reports. Five ...